Simon Kraler
skraler.bsky.social
Simon Kraler
@skraler.bsky.social
MD PhD. Prefer climbing to football, cycling to walking, Kinks to Stones. Cardiologist, scientist, editor @EJCI & editorial-board member @EHJ.
#ESCCongress 2025 #Global #Health 🇪🇸

Proud to be a #Social #Media #Ambassador for #Acute #Coronary #Syndromes & #CAD – sharing the latest science 🌍Excited to work w/ @drmilicaa @franciscojlk @rafavidalperez @liberale_luca and all other amazing colleagues👇

#CVHealthForAll❤️
🎉 The wait is almost over! #ESCCongress kicks off tomorrow!

Meet our amazing Social Media Ambassadors 🙌
Follow their journey, join the conversation, and catch the hottest updates & highlights straight from Madrid!💙
August 28, 2025 at 10:19 AM
Reposted by Simon Kraler
🚨 Excited to share that our latest study on the role of inflammatory activation in endothelial cells during the infarct response is now published in Circulation Research!

Huge thanks to all co-authors—especially Lukas, Till, Simone, and Ariane—for driving this project forward.
August 4, 2025 at 8:30 PM
Reposted by Simon Kraler
🚨 Now up
@escardio.bsky.social

Acute coronary syndromes: together w/
@dlbhattmd.bsky.social, C Mueller & P Libby we call for a precision medicine approach

🔹 Diverse mechanisms
🔹 Sex-specific differences
🔹 Shifting risk factor profiles
🔹 AI tools for personalised care

doi.org/10.1093/eurh...
May 14, 2025 at 8:21 AM
Reposted by Simon Kraler
Lepodisiran is a long-acting small interfering RNA that blocks hepatic apolipoprotein(a) production. A new Quick Take video covers the ALPACA trial’s findings in patients with elevated lipoprotein(a).

🎥 Watch now: youtu.be/B0aH0O9Pk7Q

#MedSky #CardioSky
Lepodisiran: an RNA Targeting Lipoprotein(a) (ALPACA trial) | NEJM
YouTube video by NEJM Group
youtu.be
May 3, 2025 at 7:02 PM